Financial Performance - Operating revenue for FY2024 is projected to be HK$403.73 million, representing a 1.4% increase from FY2023[13] - Revenue from innovative business is expected to reach HK$111.82 million in FY2024, reflecting a 10.8% growth compared to FY2023[13] - The average dividend per share for 2024 is set at HK$16.83 cents, with a payout ratio of 70%[13] - The company plans to make two dividend payments in 2024, totaling HK$76.03 million[13] - The company's revenue for 2024 reached RMB 403,728,000, a 1.4% increase from RMB 396,194,000 in 2023[20] - Gross profit for 2024 was RMB 233,201,000, reflecting a 4% increase from RMB 223,472,000 in 2023[20] - Net profit attributable to owners of the parent for 2024 was RMB 110,649,000, up 8% from RMB 102,032,000 in 2023[20] - Gross profit margin increased from 56.4% in FY2023 to 57.8% in the current financial year, representing an improvement of 1.4 percentage points[48] - Net profit margin rose from 25.5% in FY2023 to 27.7% in the current financial year, an increase of 2.2 percentage points[48] - The company's net profit reached approximately RMB 111.8 million, reflecting a year-on-year increase of about 10.8%[48] Business Strategy and Development - The digital and intelligent transformation in pharmacies is a key focus area for the company, enhancing operational efficiency[13] - The company is leveraging AI technology for strategic upgrades and to chart a new development blueprint[13] - The company aims to consolidate its leading edge while exploring innovative business opportunities[13] - The company aims to build a digital and intelligent health management system focused on "patient-centrism" across the entire life cycle[23] - The Company expanded its market presence by deepening its foothold in the out-of-hospital market while also growing its in-hospital innovative business[26] - The Company aims to enhance its R&D efforts and upgrade the "Woodpecker Medical Large Model" to meet customer needs with higher efficiency and quality[38] - The Company will continue to leverage AI technology to develop AI+ series products, creating long-term value for customers[125] - The Company aims to expand its strategic layout in the innovative drug and device field through investments, mergers, and acquisitions[71] Research and Development - The big data research institute will support R&D efforts, integrating data and AI technology[13] - The Company significantly increased R&D investment, focusing on AI large model development and applications, which led to substantial commercialization achievements across healthcare, pharmacies, and health management sectors[30] - R&D expenses increased by approximately 6.0% year-on-year, focusing on computing infrastructure and high-level talent recruitment[51] - The Company will continue to enhance its digital intelligence solutions for pharmaceutical and medical device enterprises to improve R&D efficiency[135] Market Presence and Client Engagement - The company has established a corporate customer network of 1,230 companies and serves over 5 million patients[20] - The Company has nearly one million industry professionals connected through its industrial ecological platform[20] - The cumulative number of pharmaceutical retail enterprises served reached 2,853, positioning the company as a market leader with continuous growth[63] - The Company served over 5,073,000 patients in 2024, a year-on-year increase of 106.39%, highlighting significant advancements in product capabilities[117] - The Company established cooperative relations with over 1,230 enterprise customers, enhancing product efficiency and achieving mutual benefits[115] AI and Technology Integration - The AI-driven "Woodpecker Medical Large Model" ranked 5th in the comprehensive list and 3rd in the complex medical reasoning sub-category on the Medbench ranking[20] - The Woodpecker AI-MDT health management solutions reached over 5.073 million people, representing a year-on-year increase of 106.39% compared to 2023[68] - The Woodpecker Medical Large Model has a total scale of weighting parameters reaching 70 billion, supported by millions of public data, tens of millions of desensitized data, and millions of labeled data[99][100] - The model has served a total of 20 million people in personalized health management through in-depth analysis of multi-source data[103] Operational Efficiency and Cost Management - The cost of sales decreased by approximately 1.3%, from approximately RMB172.7 million in FY2023 to approximately RMB170.5 million in FY2024, due to improved operational efficiency and cost control[139] - Selling and distribution expenses increased by approximately 23.7% to approximately RMB 40.1 million for the year ended 31 December 2024, attributed to business structure optimization and increased investment in talent[145] - Administrative expenses rose by approximately 11.1% to approximately RMB 38.5 million for the year ended 31 December 2024, primarily due to personnel structure optimization and increased incentives for key talents[146] Leadership and Management - Ms. Wang Lifang has over 20 years of experience in the healthcare information and data analysis industry[198] - Ms. Wang has been serving as the Executive Director and COO since June 3, 2021, overseeing daily operations and management[198] - Mr. Fu Haitao was appointed as a Non-Executive Director on June 3, 2021, with prior experience in government affairs and venture capital[197] - Ms. Wang holds a Bachelor's degree in International Economics from Harbin Institute of Technology, obtained in July 1997[199] Industry Trends and Insights - The total health expenditure in China for 2023 was only 7.2% of the total GDP, indicating significant growth potential compared to developed countries[22] - The healthcare industry is undergoing restructuring and upgrading at an accelerated pace due to AI democratization and national policies[44] - The Company was recognized as a member of the Guangdong Data Element Industry Association in February 2024, highlighting its data governance capabilities[101][102]

Core Viewpoint - Zhongkang Holdings (2361.HK) has demonstrated steady progress with a revenue of 404 million RMB, a year-on-year increase of 1.9%, and a net profit of 112 million RMB, reflecting a 10.8% growth, amidst the backdrop of AI reshaping productivity in the healthcare industry [1][2] Group 1: Market Context and Opportunities - The global capital market is experiencing a "rise of the East and fall of the West" trend, with a wave of asset revaluation centered around China, supported by domestic consumption boosts and policies favoring the healthcare industry [3][4] - Zhongkang Holdings is well-positioned to capitalize on these dual opportunities, potentially unlocking new value growth points [4][6] Group 2: Business Structure and Growth Engines - Zhongkang Holdings operates on a "three-pronged" business model, focusing on To B (business), To C (consumer), and To R (research) segments, forming a robust "iron triangle" structure [8] - The To B segment, which is the core revenue source, has seen significant growth, with innovative hospital-based business revenue reaching 48.4 million RMB, a year-on-year increase of 86.5% [10][12] - The To C segment is rapidly emerging as a new growth engine, with AI-MDT health management services reaching over 5.07 million patients, reflecting a 106% year-on-year growth [13] Group 3: Value Growth Logic - Zhongkang Holdings' core value growth logic is anchored in three key areas: scarcity, flywheel effect, and application scenarios [15] - The company holds a unique position in the healthcare data technology sector, benefiting from a near-monopoly in data infrastructure and a strong ecosystem of partnerships [16] - The flywheel effect is evident as data accumulation and model optimization enhance customer stickiness, driving long-term growth [18][19] - The company is well-positioned to benefit from the accelerated commercialization of AI in healthcare, with a focus on deep penetration into medical scenarios [20][21] Group 4: Financial Performance and Shareholder Returns - Zhongkang Holdings has a gross margin of 57.8%, up 1.4 percentage points from the previous year, indicating strong scale effects and cost efficiency driven by AI [21] - The company maintains a robust cash flow and a high dividend payout ratio of 70%, significantly above the median of the Hang Seng Technology Index, reflecting a commitment to shareholder returns [21][22]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示不會就因本公告全部或任何部分內容而產生 或因依賴該等內容而引致的任何損失承擔任何責任。 Sinohealth Holdings Limited 中康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2361） 截 至 2024 年 12 月 31 日止年度之 年度業績公告 | 財務摘要 | | | | | --- | --- | --- | --- | | | 截至12月31日止年度 | | | | | 2024年 | 2023年 | 同比變動 | | | 人民幣 | 人民幣 | | | | （千元） | （千元） | % | | 收入 | 403,728 | 396,194 | 1.9% | | 智慧決策雲 | 254,495 | 269,164 | -5.4% | | 智慧零售雲 | 88,875 | 71,564 | 24.2% | | 智慧醫療雲 | 38,254 | 41,393 | -7.6% | | 智慧健康管理雲 | 22,104 | 14,073 | 57.1% ...

Sinohealth HIdg 中康控股 中 康 控 股 有 限 公 司 Sinohealth Holdings Limited (Incorporated in the Cayman Islands with limited liability) ( 於開曼群島註冊成立的有限公司 ) Stock Code 股份代號: 2361 2024 INTERIM REPORT 中期報告 .alial SAAS Contents 目 錄 2 公司資料 | --- | --- | --- | |-------|-------------------------------------------------------------------------------------------------------|-------------------------------------------| | | | | | | Corporate Information | | | 5 | Core Financial and Operational Data | 核心財務及運營數據 | | 6 | Financial S ...

Financial Performance - Revenue for the six months ended June 30, 2024, was approximately RMB 159.5 million, representing a year-on-year increase of 10.1%[2] - Operating profit increased by approximately 62.1% year-on-year, reaching RMB 20.0 million[2] - Net profit (excluding foreign exchange gains and losses) was approximately RMB 40.1 million, up 23.2% year-on-year, with a net profit margin of 25.1%, an increase of 2.7 percentage points compared to the same period in 2023[2][4] - The company's revenue increased by approximately 10.1% from RMB 145.0 million for the period ending June 30, 2023, to RMB 159.5 million for the period ending June 30, 2024[18] - Gross profit increased by approximately 18.1% from RMB 75.2 million to RMB 88.8 million, with gross margin rising from 51.9% to 55.7%[20] - The net profit for the six months ended June 30, 2024, was RMB 42.3 million, a decrease of about 9.4% from RMB 47.0 million in 2023[38] Customer Growth and Engagement - The number of enterprise-level customers increased to 869, a growth of 3.2% compared to 842 in the same period last year, with a repurchase rate of 99.7% among top pharmaceutical and medical device clients, up 5 percentage points year-on-year[4] - The Smart Decision Cloud generated revenue of approximately RMB 68.2 million, with 412 enterprise-level customers, and a year-on-year increase in customer repurchase rate by 0.8 percentage points[6] - The number of enterprise-level customers purchasing Smart Retail Cloud services reached 519, a year-on-year growth of about 17.2%, with a repurchase rate of approximately 78.8%[7] - The AI-MDT system has reached approximately 434.5 million users for health report interpretation, an increase of about 404 million users compared to the same period in 2023[8] - The average daily processing volume of AI-MDT system health report interpretations exceeded 40,000 cases, a year-on-year increase of about 448%[8] Revenue Segmentation - Revenue from the Smart Retail Cloud segment was approximately RMB 56.4 million, showing a significant year-on-year growth of 28.8%[2] - Revenue from the Smart Health Management Cloud segment surged by 194.9% year-on-year, reaching RMB 16.9 million[2] - Revenue from data-driven publishing and events increased to RMB 38,812 thousand, up 20.9% from RMB 32,107 thousand in the previous year[49] - SaaS product revenue rose to RMB 36,707 thousand, a significant increase of 52.0% compared to RMB 24,151 thousand in the prior period[49] - Revenue from the smart retail cloud segment increased to RMB 56,437 thousand, up 28.8% from RMB 43,834 thousand in the same period last year[49] Operational Efficiency and Investments - The company has established a comprehensive digital decision-making service and product system, integrating three major data types to enhance customer insights and decision-making capabilities[6] - The company is focusing on building a digital health management system centered on patients, leveraging its core advantages in data governance and application technology[12] - The company aims to enhance its To B business by integrating "in-hospital + out-of-hospital" medical data and providing high-quality SaaS products and professional services to accelerate digital transformation for clients[13] - The company plans to develop potential and predictive models to fully exploit data value, establishing a comprehensive research system for the pharmaceutical industry[13] - The company is expanding its To C health service business, providing personalized health management and digital precision services based on big data and AI[15] Corporate Governance and Financial Management - The company has adopted the corporate governance code as per the listing rules and has complied with all applicable provisions except for the separation of the roles of Chairman and CEO, which are held by the same individual[63] - The audit committee, consisting of three independent non-executive directors, has reviewed the interim results and confirmed compliance with applicable accounting principles[67] - The company plans to utilize the remaining proceeds for the stated purposes without significant changes or delays[68] - The company is committed to reviewing its corporate governance practices regularly to ensure compliance with legal and business developments[63] Future Projections and Market Expansion - The company projects a revenue guidance of HKD 1.2 billion for the full year 2024, reflecting a 25% growth target[74] - New product launches in the SaaS segment are expected to contribute an additional HKD 100 million in revenue by Q4 2024[73] - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2025[74] - A new partnership with a leading healthcare provider aims to enhance service offerings and is expected to generate HKD 150 million in additional revenue[73] Employee and Asset Management - Employee costs amounted to approximately RMB 75.4 million, an increase of about 13.2% from RMB 66.6 million as of June 30, 2023[35] - The number of full-time employees increased to 778 as of June 30, 2024, from 698 as of June 30, 2023, reflecting a growth of approximately 11.5%[35] - Non-current assets totaled RMB 191.4 million as of June 30, 2024, compared to RMB 188.5 million as of December 31, 2023[39] - Current assets increased to RMB 620.8 million as of June 30, 2024, from RMB 609.3 million as of December 31, 2023[39] Cash Flow and Debt Management - The company maintained a strong cash position with cash and cash equivalents totaling approximately RMB 23.8 million as of June 30, 2024[30] - The company had no short-term or long-term bank borrowings as of June 30, 2024, except for lease liabilities totaling approximately RMB 13.9 million[31] - As of June 30, 2024, the debt-to-equity ratio was 19.1%, an increase from 13.9% as of December 31, 2023[32]

Financial Performance - For the year ended December 31, 2023, the revenue reached RMB 396,194,000, representing an increase of 11.1% compared to RMB 356,668,000 in 2022[15]. - Gross profit for 2023 was RMB 223,472,000, up 40.5% from RMB 159,108,000 in 2022[15]. - Net profit increased significantly to RMB 100,940,000 in 2023, compared to RMB 54,213,000 in 2022, marking an increase of 85.5%[15]. - The Group's operating revenue increased to RMB396.2 million, representing a year-on-year increase of 11.1%[38]. - Gross profit rose to approximately RMB223.5 million, reflecting a year-on-year increase of approximately 40.5%, with gross profit margin increasing from 44.6% in FY2022 to 56.4%[38]. - Profit for the year surged by 86.2% year-on-year to RMB100.9 million, with net profit margin increasing by 10.3 percentage points year-on-year to 25.5%[38]. - The Group's profit for the year increased by approximately 86.2%, from approximately RMB54.2 million in 2022 to approximately RMB100.9 million in 2023[124][129]. - Other income and gains increased by approximately 9.5%, from approximately RMB37.7 million in 2022 to approximately RMB41.3 million in 2023, mainly due to an increase in bank interest income[115][118]. Asset Management - Non-current assets rose to RMB 188,477,000 in 2023, a substantial increase from RMB 94,285,000 in 2022[15]. - Current assets decreased to RMB 609,264,000 in 2023 from RMB 702,188,000 in 2022, reflecting a decline of 13.3%[15]. - The total equity of the company was RMB 700,454,000 in 2023, slightly up from RMB 693,236,000 in 2022[15]. - Cash and cash equivalents decreased by approximately 69.7%, amounting to approximately RMB123.9 million as of 31 December 2023, primarily due to the placement of idle funds in time deposits[132][137]. - The gearing ratio was approximately 13.9% as of 31 December 2023, a slight decrease from approximately 14.9% as of 31 December 2022[134]. - The Group had no short-term or long-term bank borrowings as of December 31, 2023, apart from lease liabilities totaling approximately RMB14.2 million[133][138]. Market and Industry Insights - The healthcare industry in China is projected to grow from RMB 9 trillion in 2022 to RMB 16 trillion by 2030, with the serious medical industry reaching RMB 9.6 trillion and consumer medical industry reaching RMB 6.4 trillion[22]. - The serious medical industry is expected to have a CAGR of 5.8%, while the consumer medical industry is projected to grow at a CAGR of 9.8%[22]. - The healthcare industry is expected to experience explosive growth in health big data and digital products, reshaping the industry profile in China[16]. - The rapid growth of the data-driven economy is expected to increase demands for data insights and digital services in the healthcare industry[22]. Technology and Innovation - The company is focusing on developing three core technologies: big data, artificial intelligence, and cloud computing to enhance healthcare industry efficiency[16]. - The Group provided more than 30 SaaS products and professional insight services, enhancing data governance capabilities and enabling efficient decision-making for medical product suppliers[18]. - The Smart Medical Cloud achieved an operating revenue of approximately RMB41.4 million in the financial year, representing a year-on-year increase of approximately 12% compared to FY2022[66]. - The self-developed Lingsu System achieved a market data response time of T+3, positioning the company at a leading level in the industry[46]. - The AI-MDT system will continue to innovate and expand its functions, providing comprehensive health management services to physical examination institutions and hospitals[99]. Customer and Market Expansion - The number of corporate customers reached 1,288, an increase of 44.6% from 891 in the same period of FY2022, with a repurchase sales rate of leading customers at 95.7%[34]. - The number of cooperative pharmacies increased by 22% year-on-year, with over 100,000 pharmacy stores established for SIC products, maintaining a rapid growth trend[50]. - The Smart Decision Cloud service had 804 corporate customers as of December 31, 2023, representing a year-on-year increase of approximately 39.6%, with a repurchase sales rate of 88.9%[41]. - The Group's medical retail cooperative network reached 1,735 partnering medical retail enterprises and 129,555 partnering pharmacy stores as of December 31, 2023, representing a year-on-year increase of 16% and 22%, respectively[75]. Corporate Governance and Management - The company has a strong governance structure with multiple committees including Audit and Remuneration Committees[180]. - The management team includes professionals with extensive backgrounds in finance and management, enhancing strategic decision-making capabilities[175]. - The company emphasizes the importance of independent judgment in management oversight through its board members[184][185]. - The Group has developed a comprehensive vocational training system and a sound remuneration and promotion system to attract and retain talent[152]. Strategic Initiatives - The Group aims to build three development curves: To B, To C, and To R, focusing on data-driven digital services for the healthcare industry[27]. - The strategy includes enhancing technical innovation and establishing long-term cooperative relationships with customers[27]. - The Group plans to leverage its core advantages in data governance and application technology to accelerate the development of a patient-centered digital health management system[87]. - The Group will focus on three major development directions: expanding corporate business (To B), enhancing customer-end health services (To C), and creating a digital empowerment platform for biomedical R&D (To R)[89].

Financial Performance - Revenue increased by 11.1% year-on-year to RMB 396.2 million in 2023[2][4] - Gross profit grew by 40.5% to RMB 223.5 million, with gross margin rising from 44.6% to 56.4%[4] - Net profit surged by 86.2% to RMB 100.9 million[2][4] - Revenue increased by 11.1% from RMB 356.7 million in 2022 to RMB 396.2 million in 2023, driven by growth in the Smart Decision Cloud business[23] - Cost of sales decreased by 12.6% from RMB 197.6 million in 2022 to RMB 172.7 million in 2023 due to improved operational efficiency[24] - Gross profit increased by 40.5% from RMB 159.1 million in 2022 to RMB 223.5 million in 2023, with gross margin rising from 44.6% to 56.4%[25] - Other income and gains increased by 9.5% from RMB 37.7 million in 2022 to RMB 41.3 million in 2023, primarily due to higher bank interest income[26] - Profit before tax surged by 103.3% from RMB 54.5 million in 2022 to RMB 110.7 million in 2023, mainly due to increased gross profit[30] - Net profit for the year rose by 86.2% from RMB 54.2 million in 2022 to RMB 100.9 million in 2023[32] - Revenue for 2023 increased to RMB 396.194 million, up from RMB 356.668 million in 2022, with gross profit rising to RMB 223.472 million from RMB 159.108 million[44] - Net profit for 2023 was RMB 100.940 million, compared to RMB 54.213 million in 2022[44] - Total revenue for 2023 reached RMB 396.194 million, a 11.1% increase from RMB 356.668 million in 2022[54] - Pre-tax profit for 2023 increased to RMB 110,741 thousand, up from RMB 54,474 thousand in 2022, reflecting significant growth[68] - The actual tax rate for 2023 was 8.9%, compared to 0.5% in 2022, indicating a substantial increase in tax expenses[68] Business Segments Performance - Revenue from the Smart Decision Cloud segment grew by 47.3% to RMB 269.2 million, with 804 enterprise clients and an 88.9% repurchase rate[2][7] - The Smart Retail Cloud segment revenue decreased by 43.4% to RMB 71.6 million[2] - The Smart Medical Cloud segment revenue increased by 12.0% to RMB 41.4 million[2] - The Smart Health Management Cloud segment revenue grew by 34.6% to RMB 14.1 million[2] - Smart Decision Cloud revenue surged by 47.3% to RMB 269.164 million in 2023[56] - Data Insight Solutions revenue decreased to RMB 195.741 million in 2023 from RMB 225.262 million in 2022, a 13.1% decline[56] - Data-Driven Publishing & Events revenue increased by 57.9% to RMB 143.616 million in 2023[56] - SaaS product revenue grew by 40.4% to RMB 56.837 million in 2023[56] - Revenue from services transferred at a point in time increased to RMB 169.924 million in 2023, up 28.7% from 2022[56] Client and Market Expansion - The number of enterprise-level clients increased by 44.6% to 1,288, with a 95.7% repurchase rate among top pharmaceutical and medical device clients[4] - Signed but not yet executed contracts totaled over 500, amounting to approximately RMB 154.1 million, a 79.2% increase year-on-year[4] - The company's SIC products have established partnerships with over 100,000 pharmacy stores as of December 31, 2023, representing a 22% year-over-year growth[8] - The company's smart retail cloud SaaS products have helped 622 enterprise-level clients, a 51.7% increase compared to the previous fiscal year, with an overall repurchase rate of 84.6%[9] - The company's data network covers over 120,000 pharmacy stores across 30 provinces and 349 cities, with total sales from partnered pharmacies exceeding 160 billion yuan in 2023, accounting for approximately 30% of the national total sales[12] - 80% of the partnered pharmacy stores provide real-time data, and over 80% of the stores offer real-time order-level data[12] - The number of partnered pharmacy stores increased by 22% year-over-year to 129,555 as of December 31, 2023[14] - The number of pharmacy employees increased by 25% year-over-year to 239,000 as of December 31, 2023[14] Technology and Innovation - The AI-MDT system, which integrates expertise from over 300 specialists across 16 disciplines, covers 31 disease categories, 1,770 diseases, and 801 single indicators, and has a daily processing capacity of over 30,000 health reports[10] - The company's data processing platform, Sinohealth-Engine, has a machine auto-cleaning rate of over 97% and an accuracy rate exceeding 99%, with the fastest response time reaching T+1[14] - The company has established 38 standardized and structured master databases covering various health industry sectors, including pharmaceutical retail, regulatory, medical, and life sciences[14] - The company's "Tiangong-1" commercial data intelligence platform and "Zhumuniao" smart health management platform enhance data value mining capabilities[14] - AI-MDT refers to the customized health management solution provided by the company for physical examination users, utilizing AI technology for multidisciplinary analysis and evaluation of user reports[86] - The company's smart decision cloud product, Lingtong, helps customers efficiently formulate marketing strategies, improve marketing effectiveness, and track results in real-time[87] - The company's smart retail cloud product, SIC, provides comprehensive services including business management, membership management, and intelligent marketing for pharmacies[88] - The company's smart retail cloud product, Yilingtong, offers customized data-driven marketing solutions, enhancing marketing effectiveness and tracking results in real-time[89] Financial Position and Capital Management - Cash and cash equivalents decreased by 69.7% to RMB 123.9 million as of December 31, 2023, due to the placement of idle funds into fixed deposits[34] - The company has no short-term or long-term bank borrowings, with only RMB 14.2 million in lease liabilities[36] - The asset-liability ratio decreased to 13.9% as of December 31, 2023, from 14.9% in 2022[37] - Capital expenditures decreased by 18.5% to RMB 3.4 million in 2023, primarily for equipment, software acquisition, and leasehold improvements[39] - The company had no significant contingent liabilities, guarantees, or major litigation as of December 31, 2023[40] - Total non-current assets increased to RMB 188.477 million in 2023 from RMB 94.285 million in 2022, driven by growth in property, plant, and equipment, and fixed deposits[45] - Total current assets decreased to RMB 609.264 million in 2023 from RMB 702.188 million in 2022, primarily due to a reduction in cash and cash equivalents[45] - Total equity increased slightly to RMB 700.454 million in 2023 from RMB 693.236 million in 2022[46] - The company's shares were listed on the Hong Kong Stock Exchange on July 12, 2022[49] - The company issued 75,000,000 shares at a price of HKD 5.36 per share during its IPO on July 12, 2022, raising approximately USD 47.47 million (equivalent to approximately RMB 319.40 million) after deducting listing expenses[75] - A capital increase of 370,000,000 shares was issued at par value on the listing date, with RMB 24.90 million allocated from the share premium account[75] - The company repurchased 20,585,500 shares in 2022 for a total consideration of approximately HKD 112.87 million (equivalent to approximately RMB 101.12 million) under the share award scheme[76] - In 2023, the company repurchased 16,210,500 shares for a total consideration of approximately HKD 86.46 million (equivalent to approximately RMB 77.98 million) under the share award scheme[76] - The board proposed a final dividend of HKD 0.0725 per share for the year ended December 31, 2023, payable on September 25, 2024[78] - The proposed final dividend per share increased to 7.25 HK cents in 2023 from 3.98 HK cents in 2022, indicating improved shareholder returns[68] - The weighted average number of ordinary shares used for basic earnings per share calculation increased to 426,125,312 in 2023 from 410,666,838 in 2022[68] Corporate Governance and Compliance - The company has adopted the principles and provisions of the Corporate Governance Code, except for the separation of the roles of Chairman and CEO[80] - The company has established an audit committee consisting of three independent non-executive directors, with Mr. Wei Bin as the chairman[84] - The annual report containing all information required by the listing rules will be sent to shareholders and published on the company's website[85] - The company will suspend share registration from June 14, 2024, to June 19, 2024, for the 2024 Annual General Meeting[79] - Share registration will also be suspended from June 26, 2024, to June 27, 2024, to determine shareholders eligible for the proposed final dividend[79] Employee and Operational Metrics - The company's total number of full-time employees increased to 759 in 2023, up from 680 in 2022, with employee costs rising by 1.4% to RMB 148.0 million[41] - Employee distribution by function: 43% in solutions and products, 31% in R&D, 16% in sales and marketing, and 10% in general and administrative roles[42] - The company acquired a 50.6% stake in Guangzhou Zhonghui Medical Technology for RMB 12,238,921 on February 5, 2024[43] Industry and Market Trends - China's digital economy reached 50.2 trillion yuan in 2022, accounting for 41.5% of GDP, with a nominal growth rate of 10.3% year-on-year[16] - The "Data Element X" three-year action plan (2024-2026) aims for an average annual growth rate of over 20% in the data industry and a doubling of data transaction scale by 2026[16] - The company's health industry platform, including the "Xipu Conference," has become a leading industry event in China, with over 100,000 professionals in the pharmaceutical retail, medical device, and healthcare sectors[15] - The company successfully held the first "Traditional Chinese Medicine Ecological Conference" in December 2023, extending its industry platform resources to the upstream and downstream of the traditional Chinese medicine industry chain[15] Future Development and Strategy - The company will focus on three main development directions: expanding To B business, developing To C health services, and building a To R digital empowerment platform for biopharmaceutical R&D[17] - The company plans to enhance its Smart Decision Cloud by introducing more B2C and O2O data sources, developing predictive models, and providing data visualization SaaS tools[18] - The Smart Retail Cloud will help pharmaceutical retail enterprises improve staff management, member engagement, and sales efficiency through digital transformation[19] - The company's AI-MDT system will provide digital solutions for体检机构 and hospitals, aiming to serve 870 million体检人次 annually in China[20] Financial Risks and Credit Management - Trade receivables for 2023 amounted to RMB 111,351 thousand, up from RMB 92,028 thousand in 2022, showing an increase in credit sales[69] - The impairment loss on trade receivables increased to RMB 23,530 thousand in 2023 from RMB 6,322 thousand in 2022, due to higher overdue balances[70] - The expected credit loss rate for trade receivables over 1 year increased to 78.9% in 2023 from 65.9% in 2022, indicating higher credit risk[73] - Trade payables decreased to RMB 13,109 thousand in 2023 from RMB 14,665 thousand in 2022, reflecting a reduction in outstanding payments[73] - The company's credit terms with customers generally range from 7 to 120 days, with strict controls over outstanding receivables[69] Tax and Regulatory Environment - Tax expenses in Mainland China for 2023 were RMB 11,114 thousand, a sharp increase from RMB 1,880 thousand in 2022[65] - Certain subsidiaries in Mainland China were recognized as small and micro enterprises, benefiting from a preferential tax rate of 5%[66] Shareholder and Investor Relations - The company's issued and fully paid ordinary shares remained unchanged at 451,770,000 shares in both 2023 and 2022[74] - The proposed final dividend per share increased to 7.25 HK cents in 2023 from 3.98 HK cents in 2022, indicating improved shareholder returns[68] - The weighted average number of ordinary shares used for basic earnings per share calculation increased to 426,125,312 in 2023 from 410,666,838 in 2022[68] - The board proposed a final dividend of HKD 0.0725 per share for the year ended December 31, 2023, payable on September 25, 2024[78] - The company will suspend share registration from June 14, 2024, to June 19, 2024, for the 2024 Annual General Meeting[79] - Share registration will also be suspended from June 26, 2024, to June 27, 2024, to determine shareholders eligible for the proposed final dividend[79]

Revenue and Financial Performance - Revenue for the first half of FY2023 reached approximately 888.15 million, accounting for a 31.1% share of the total retail pharmacies in China[9] - Revenue for the six months ended June 30, 2023, was RMB 144,950,000, representing a year-on-year increase of 19.6% compared to RMB 121,209,000 in 2022[16] - The Group's revenue increased by approximately 19.6% from approximately RMB121.2 million for the six months ended June 30, 2022, to approximately RMB145.0 million for the same period in 2023[49] - Gross profit for the six months ended June 30, 2023, amounted to approximately RMB75.2 million, representing an increase of approximately 32.7% compared to approximately RMB56.7 million for the same period in 2022[49] - The Group's gross profit margin increased by 5.2 percentage points from approximately 46.7% for the six months ended June 30, 2022, to approximately 51.9% for the same period in 2023[49] - Profit before tax significantly increased to RMB 47,892, compared to RMB 3,926 in 2022, marking a substantial rise of 1,120.5%[200] - Profit for the period was RMB 46,970, a notable increase from RMB 5,287 in 2022, reflecting a growth of 790.5%[200] - The attributable profit to owners of the parent was RMB 47,833, compared to RMB 3,860 in the prior year, showing an increase of 1,138.5%[200] Cloud Services and Technology - The Smart Decision Cloud generated revenue of RMB 72,073,000, accounting for 49.7% of total revenue, with a year-on-year growth of 32.6%[16] - The Smart Health Management Cloud saw significant growth, with revenue increasing by 799.4% to RMB 5,729,000, accounting for 4.0% of total revenue[16] - The Smart Retail Cloud revenue decreased by 5.2% to RMB 43,834,000, representing 30.2% of total revenue[16] - The Group aims to continuously expand its leading edge in big data, artificial intelligence, and cloud computing technologies in the healthcare sector[46] - The Smart Medical Cloud will integrate existing resources to support the commercialization of innovative pharmaceutical and medical devices, focusing on the full life-cycle from clinical development to post-launch marketing[102] Market Expansion and Partnerships - The company aims to expand its market presence through strategic partnerships and technological advancements in health management[9] - The company has partnered with six top-tier hospitals and 38 clinical departments, serving over 200,000 patients[8] - The Group entered into a strategic cooperation agreement with Shenzhen Data Exchange to explore new paths for data circulation and trading in the healthcare industry[44][45] - The company plans to expand its services to more medical institutions and health management organizations in additional cities to serve a larger population[83] Data Management and Analysis - The Smart Health Management Cloud has processed and analyzed over 200,000 physical examination data from more than 650 private physical examination centers[8] - The database storage capacity has exceeded 32TB, enhancing data management capabilities[10] - The company has developed 38 master databases covering healthcare industry data, storing and analyzing over 32TB of data[21] - The company processed and analyzed over 210 million data records per month, ensuring efficient data governance[30] - The knowledge graph covered 7,764 diseases as of June 30, 2023, enhancing the company's data processing capabilities[30] User Engagement and Service Utilization - The interim report highlights a significant increase in user engagement and service utilization across its platforms[9] - The number of active pharmacy consumers managed through SIC grew to 329,092, a significant increase of 42.3% year-on-year[26] - The number of staff using the SIC mobile app reached 223,000, marking a 16.1% increase compared to the previous year[26] - The total number of retail sales entries collected through SIC was 176 million, representing a 33.3% increase from 132 million in the previous year[26] Corporate Governance and Management - The Company is committed to good corporate governance practices, ensuring transparency and accountability to shareholders[157] - The Company does not have a separate chairman and CEO, with Mr. Wu Yushu performing both roles, which the Board believes ensures consistent leadership[158] - The Group's employee remuneration includes basic salary, performance bonuses, and allowances, determined by factors such as competency and performance[152] Future Outlook and Strategic Goals - Future outlook includes plans for further market expansion and the introduction of new health management technologies[9] - The Group aims to enhance marketing effectiveness and R&D efficiency through technological innovation, focusing on efficient decision-making and precise connection in the healthcare industry[91] - The Group intends to develop customized products and services for key customers, increasing the number of products per customer and achieving growth in both the number of industry-leading customers and unit price[95] Financial Position and Cash Flow - As of June 30, 2023, the Group's total cash and cash equivalents amounted to approximately RMB 199.2 million, representing a decrease of approximately 51.3% from RMB 409.3 million as at 31 December 2022[135] - The Group's gearing ratio was 18.2% as at 30 June 2023, compared to approximately 14.9% as at 31 December 2022[137] - The Group did not have any short-term or long-term bank borrowings as of 30 June 2023, apart from lease liabilities amounting to approximately RMB 16.7 million[136] Research and Development - Research and development costs decreased by approximately 4.5% from approximately RMB28.5 million for the six months ended June 30, 2022, to approximately RMB27.2 million for the six months ended June 30, 2023[126] - The Group aims to establish industry benchmarks and leading capabilities in the healthcare industry, focusing on improving product quality and professional service capabilities[110] Shareholder Information - As of June 30, 2023, the total number of shares issued by the company is 451,770,000[1] - The share option scheme adopted on April 27, 2022, has 45,000,000 options available for grant, with no options granted, exercised, expired, or lapsed since the listing date[184] - The Group received net proceeds from the Global Offering of approximately HK$339.6 million, which will be utilized as outlined in the Prospectus[195]

[5 -> 32] 大家好 欢迎参加中康控股2023年中报业绩交流会目前所有参会者均处于静音状态下面开始播报免责声明本次会议仅服务于邀请参会的广大投资者会议音频及文字记录的内容仅供参会者内部使用不得公开发布中康控股未授权任何媒体转发本次会议相关内容未经允许和授权的转载转发均属侵权 [32 -> 62] 中康控股将保留追究其法律责任的权利中康控股不承担因转载转发而产生的任何损失和责任市场有风险投资需谨慎提醒广大投资者谨慎做出投资决策在会议开始前我们提示各位投资者在主讲嘉宾发言结束后将留有提问时间首先介绍今天参与本次交流会的公司领导他们是公司CFO兼联席公司秘书易旭辉女士 [62 -> 91] 公司IR负责人万川先生下面有请公司领导发言谢谢各位投资者下午好感谢参与参加我们中央控股在2023年的一个中期的业绩交流会中央控股是 [92 -> 121] 立足于基于大数据人工智能和云计算对生命科学领域的一个效率提升提供数字化一体化解决方案的一家公司我们今天的分享分为三个部分第一部分是我们的经营今年上半年的经营亮点第二点的话是我们对整个行业趋势做一个研判第三是我们会说一下我们未来的一个经营计划 [130 -> 155] 我 ...

B_table indent_4.5 mm N_table indent_4 mm 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 不 會 就 因 本 公 告 全 部 或 任 何 部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Sinohealth Holdings Limited 中 康 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2361） | --- | --- | --- | --- | --- | --- | |----------------|------------------|---------------|------------------|----------|----------| | | | | | | | | 主要財務業績 | | | | | | | | | 截 至 月 | 止六個月 | | | | | 2023 年 | 6 30 佔總收入 | 2022 年 | 佔總收入 | | | | （未經審核） | 百分比 | （未經審核） ...